‪‎ChoiceBroking‬ ‪‎Financial‬ Tips Morning Tea ‪‎Buy‬ ‪‎AXISBANK‬ @444-447 ‪TGT‬ 457 ‪‎SL‬ 439 BUY ‪‎AUROPHARMA‬ @ 836-841 TGT 858 SL 827

1. SEBI Certified – Research Analyst www.choiceindia.com
Global View
India Update
Today’s Event/ Stock in News
Axis Bankhaspartnered with digital security company eMudhra forthe eSign service. The bankhas introduced e-signature servicesthrough which
individuals having Aadhaar numbers will be able to digitally sign documents to submit to the bank online. The service rides on Aadhaar
authentication and generates the digital signature automatically. The generated signature is legally valid and secure. Axis Bank is the third largest
private sector bank in India. The bank offers the entire spectrum of financial services to customer segments covering Large and Mid-Corporates,
MSME,AgricultureandRetailBusinesses.
Technical Outlook : On daily chart, stock has given breakout of 443.65 level and managed to close above that level, which shows that
upside movement can be seen in next trading session. Moreover, volume has also increased with rise in price, which validates the
breakout.AmomentumindicatorRSIreadingisat43.60levelwithpositivecrossover,whichpointoutforpositivebreathinthestock.Sofor
tradingperspective,onecouldBuyintherangeof444-447fortheTargetof457withtheSLof439.
AXISBANK
AUROPHARMA
SEBI Registered – Research Analyst www.choiceindia.com * Please Refer Disclaimer on Website
Morning Tea
23rd Dec 2015
Buy in the range of 836-841 for the Target of 858 with the SL of 827
Buy in the range of 444-447 for the Target of 457 with the SL of 439
DrugmakerAurobindoPharmaLtdonTuesdaysaidithasreceivedfinalapprovalfromtheUSFood&DrugAdministration(USFDA)tomanufacture
and market anti-allergic drug.“The company has received final approval from the US Food & Drug Administration (USFDA) to manufacture and
market Olopatadine Hydrochloride Ophthalmic Solution USP, 0.1%,” Aurobindo Pharma Ltd said in a filing to the Bombay Stock Exchange on
December 22, 2015. The approved ANDA is bioequivalent and therapeutically equivalent to the reference listed drug product (RLD) Patanol
Ophthalmic Solution/Drops, 0.1 per cent, of Alcon Laboratories, Inc, the company said in a statement. The company further said that Olopatadine
Hydrochloride Ophthalmic solution is used in the treatment of the signs and symptoms of seasonal allergic conjunctivitis. Moreover, the company
saidthatthisisthe20thANDA(includingonetentativeapproval)approvedoutofUnitIVformulationfacilityinHyderabad,Indiaformanufacturing
generalinjectableproducts.TheproducthasanestimatedmarketsizeofUSD235millionforthetwelvemonthsendingOctober2015accordingto
IMS.
Technical Outlook : On daily chart, stock has been continuously trading above its 21 Day Moving Average (which is placed at 822), which indicates
that near term trend is up. on hourly chart, stock has been continuously trading in higher top higher bottom formation, which also confirms the
uptrend of stock. A momentum indicator RSI reading is at 59.45 with positive crossover, which point out for positive breath in the stock. so for
tradingperspective,onecouldBuyintherangeof836-841 fortheTargetof858 withtheSLof827.
Wall Street rallied across the board on Tuesday after oil prices recovered slightly and data showed that the US economy grew at a
fairly healthy clip in the third quarter. Oil prices edged up from 11-year lows although persistent global oversupply concerns and
tepiddemandforheatingoilremainedinwhatislikelytobethewarmestwinteronrecord.Intheabsenceofthegiftofasustained,
late-yearrallydesiredbymanyonWallStreet,theS&P500haslost2percentinDecember.
Indian stocks are likely to open higher, following an up-move in both Asian markets as well as on Wall Street overnight, as risk-on
sentimentset inthankstoapauseintheUSdollar rallyandasoil prices reboundedoff 11-year lows. InSingapore,theSGX Niftywas
trading0.6percent,or47.5points,higherto7,831.Tradingvolumes,however,areexpectedtobelightasfestive-seasonholidaysset
in inthe West. Closer home, Indian investors will focuson developments inParliament, whose Winter Session ends today --even as
passageofcrucialbillssuchasGSTandbankruptcybillsareunlikelytobepassedtoday.

2. SEBI Certified – Research Analyst www.choiceindia.com
Bulk Deal
Corporate Action / Result Calendar
SEBI Certified – Research Analyst www.choiceindia.com
Morning Tea
Corporate Action:
Power Finance Corporation Limited; Interim Dividend - Rs 8.80/- Per Share (Purpose
Revised)
Opto Circuits (India) Limited; Annual General Meeting
Result Calendar:
23rd Dec 2015
Security in Ban
SEBI Registered – Research Analyst www.choiceindia.com * Please Refer Disclaimer on Website
Sr. No. Deal Date Script Code Security Name Client Name Deal Type Quantity Price
1 22/12/2015 534060 PMCFIN PARESH RAMJIBHAI CHAUHAN S 6192989 0.61
2 22/12/2015 534060 PMCFIN PARESH RAMJIBHAI CHAUHAN B 6192989 0.60
3 22/12/2015 530131 UDAICEMENT MORGAN STANLEY ASIA (SINGAPORE) PTE S 4384939 12.56
4 22/12/2015 534060 PMCFIN VIBRANT SECURITIES PRIVATE LIMITED B 3927738 0.62
5 22/12/2015 534060 PMCFIN VIBRANT SECURITIES PRIVATE LIMITED S 3827738 0.62
6 22/12/2015 534060 PMCFIN SEABIRD VINCON PRIVATE LIMITED S 3500000 0.60
7 22/12/2015 534060 PMCFIN SHIVDARSHAN SALES PRIVATE LIMITED S 2500000 0.60
8 22/12/2015 511523 VEERHEALTH SUMTINATH SHARES AND SERVICES PRIVATE LI B 600000 3.37
9 22/12/2015 531977 CHLOGIST KISHORKUMAR KUMAR GANDHI S 500000 20.00
10 22/12/2015 531977 CHLOGIST CHARTERED MOTORS PRIVATE LIMITED B 500000 20.00
INDIACEM, JINDALSTEL, JISLJALEQS, JPASSOCIATE & UNITECH

3. SEBI Certified – Research Analyst www.choiceindia.com
Contact Us
www.choiceindia.com
www.choiceindia.comcustomercare@choiceindia.com
Disclaimer
This is solely for information of clients of Choice Broking and does not construe to be an investment advice. It is also not intended as an offer or solicitation for the purchase and sale of any financial
instruments. Any action taken by you on the basis of the information contained herein is your responsibility alone and Choice Broking its subsidiaries or its employees or associates will not be liable in
any manner for the consequences of such action taken by you. We have exercised due diligence in checking the correctness and authenticity of the information contained in this recommendation, but
Choice Broking or any of its subsidiaries or associates or employees shall not be in any way responsible for any loss or damage that may arise to any person from any inadvertent error in the
information contained in this recommendation or any action taken on basis of this information. Technical analysis studies market psychology, price patterns and volume levels. It is used to forecast
future price and market movements. Technical analysis is complementary to fundamental analysis and news sources. The recommendations issued herewith might be contrary to recommendations
issued by Choice Broking in the company research undertaken as the recommendations stated in this report is derived purely from technical analysis. Choice Broking has based this document on
information obtained from sources it believes to be reliable but which it has not independently verified; Choice Broking makes no guarantee, representation or warranty and accepts no responsibility
or liability as to its accuracy or completeness. The opinions contained within the report are based upon publicly available information at the time of publication and are subject to change without
notice. The information and any disclosures provided herein are in summary form and have been prepared for informational purposes. The recommendations and suggested price levels are intended
purely for trading purposes. The recommendations are valid for the day of the report however trading trends and volumes might vary substantially on an intraday basis and the recommendations may
be subject to change. The information and any disclosures provided herein may be considered confidential. Any use, distribution, modification, copying, forwarding or disclosure by any person is
strictly prohibited. The information and any disclosures provided herein do not constitute a solicitation or offer to purchase or sell any security or other financial product or instrument. The current
performance may be unaudited. Past performance does not guarantee future returns. There can be no assurance that investments will achieve any targeted rates of return, and there is no guarantee
against the loss of your entire investment.
POTENTIAL CONFLICT OF INTEREST DISCLOSURE (as on date of report) Disclosure of interest statement – • Analyst interest of the stock /Instrument(s): - No. • Firm interest of the stock /
Instrument (s): - No.
SEBI Certified – Research Analyst www.choiceindia.com
Research Team
Mr. Sumeet Bagadia Associate Director
Kunal Parmar Research Associate
Amit Pathania Research Associate
Vikas Chaudhari Research Associate
Kapil Shah Research Associate
Rajnath Yadav Research Associate
Satish Kumar Research Associate
Morning Tea
23rd Dec 2015
SEBI Registered – Research Analyst www.choiceindia.com * Please Refer Disclaimer on Website